NMI-900 is under clinical development by Nemucore Medical Innovations and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NMI-900’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NMI-900 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NMI-900 overview

NMI-900 (GSK1070916) is under development for the treatment of acute myeloid leukemia, breast cancer, chronic myelocytic leukemia, myelodysplastic syndrome, non-small cell lung cancer, ovarian cancer and refractory solid tumors. The drug candidate is administered intravenously. It is formulated as a nanoemulsion and targets aurora kinase B (AURKB) and C (AURKC). It was also under development for the treatment of ovarian cancer.

Quick View NMI-900 LOA Data

Report Segments
  • Innovator
Drug Name
  • NMI-900
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.